Literature DB >> 18059347

Management of renal stone disease in obese patients.

Aleksandra Vujovic1, Stephen Keoghane.   

Abstract

Obesity represents an increasing burden to health care resources. Nephrolithiasis is associated with obesity and type 2 diabetes and the consumption of diets rich in protein, fat and carbohydrates; this article addresses some of the pathophysiological mechanisms associated with stone formation in these patients. Management of stone disease can be more difficult in obese patients; even diagnosis can be problematic because imaging techniques are less sensitive in these patients. Treatment with extracorporeal shockwave lithotripsy and surgery in obese patients can be challenging, and outcome data for the different treatments are discussed in this Review.

Entities:  

Mesh:

Year:  2007        PMID: 18059347     DOI: 10.1038/ncpuro0988

Source DB:  PubMed          Journal:  Nat Clin Pract Urol        ISSN: 1743-4270


  5 in total

1.  Impact of body mass index on clinical outcomes associated with percutaneous nephrolithotomy.

Authors:  Fahad A Alyami; Thomas A A Skinner; Richard W Norman
Journal:  Can Urol Assoc J       Date:  2013-04-16       Impact factor: 1.862

2.  The difficult ureter: what is the incidence of pre-stenting?

Authors:  R J Cetti; S Biers; S R Keoghane
Journal:  Ann R Coll Surg Engl       Date:  2010-10-08       Impact factor: 1.891

Review 3.  An overview of kidney stone imaging techniques.

Authors:  Wayne Brisbane; Michael R Bailey; Mathew D Sorensen
Journal:  Nat Rev Urol       Date:  2016-08-31       Impact factor: 14.432

4.  Does body mass index effect the success of percutaneous nephrolithotomy?

Authors:  Abdülmuttalip Şimşek; Faruk Özgör; Mehmet Fatih Akbulut; Onur Küçüktopçu; Ahmet Yalçın Berberoğlu; Ömer Sarılar; Murat Binbay; Ahmet Yaser Müslümanoğlu
Journal:  Turk J Urol       Date:  2014-06

5.  Metabolic Syndrome and Nephrolithiasis Risk: Should the Medical Management of Nephrolithiasis Include the Treatment of Metabolic Syndrome?

Authors:  John Michael DiBianco; T W Jarrett; Patrick Mufarrij
Journal:  Rev Urol       Date:  2015
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.